Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A user is using RU58841 and pyrilutamide for hair loss and is seeing their hairline return, but the process is slow. They also mention using finasteride and dutasteride, with finasteride causing reduced libido but no noticeable side effects from RU58841 or pyrilutamide.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Low vitamin D levels can negatively impact hair growth, and supplementing with vitamin D, along with treatments like finasteride and minoxidil, may help improve hair health. Quitting smoking and ensuring adequate vitamin B12 and K2 intake are also suggested to support hair regrowth.

Creatine may increase DHT levels, potentially affecting hair loss in some individuals, but opinions vary. Some users report hair loss while on creatine, while others see no effect, especially when using treatments like finasteride, minoxidil, and microneedling.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation discusses the effectiveness of RU58841 and pyrilutamide for hair loss treatment. It seeks personal success or failure stories and scientific data on these treatments.

Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.

The user is experiencing scalp itching despite using finasteride and Ketoconazole shampoo for hair loss and seborrheic dermatitis. They are unsure if the itch is due to their treatments, diet, or mental factors.

The user has been experiencing severe scalp itching and red spots after using finasteride for two years, suspecting possible allergies or a fungal infection. Despite trying ketoconazole shampoo and stopping saw palmetto supplements, the symptoms persist, leading to increased hair loss.

A user with diffuse hair loss for a decade tried various treatments, including LLLT Helmet, supplements, topicals, and hair transplants. They found relief from scalp inflammation and itching using a topical solution made from crushed Xeljanz pills mixed with ethyl alcohol.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.

Treatments for hair loss, including the effectiveness and safety of Pyrilutamide compared to RU58841; experiences using both medications with varying results; and recommendations to try Pyrilutamide instead of RU58841.

A 30-year-old woman with a history of anemia and low vitamin D experienced hair shedding, which improved after addressing nutrient deficiencies. Despite regrowth of terminal hairs, her dermatologist recommended treatments like minoxidil and spironolactone to prevent future bald spots, but she is cautious due to family history of hormone-related cancers.

The post and conversation are about skepticism towards HairClone's crowdfunding campaign for a hair loss cure, with users expressing doubt and calling it a scam. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A user shared progress pictures after almost 3 months of using dutasteride, minoxidil, stemoxydine, and tretinoin for hair loss, reporting positive results and no significant side effects. The user chose dutasteride over finasteride due to early balding and noted benefits like better skin and increased libido.

A 21-year-old male with a thyroid condition noticed his hair thinning uniformly without a receding hairline. He is considering using a 5ARI to prevent further baldness if he starts TRT.

A 15-year-old experiencing severe diffuse thinning plans to use minoxidil, dermarolling, and possibly ketoconazole, with hopes to later incorporate finasteride. Concerns about starting finasteride too young and the need for a dermatologist consultation are discussed.

A user started using oral minoxidil (2.5 mg) and dutasteride (1 mg) for hair loss three months ago and noticed no side effects, possibly due to regular exercise. They speculate a possible link between COVID-19 and accelerated hair loss.

The user has been using a hair loss treatment including oral Minoxidil, topical Minoxidil with Tretinoin and Finasteride, and is considering adding Dutasteride but is concerned about the potential side effects and risks regarding fertility. A reply suggests that having children while on these medications should be fine, advising to avoid letting the partner come into contact with the drugs.

The conversation is about a person experiencing treatment-resistant androgenic alopecia despite using high doses of dutasteride and minoxidil, along with other treatments like microneedling and purilutamide. Suggestions include considering a hair transplant, checking medication authenticity, and exploring other treatments like RU58841 or topical estradiol.

The user experienced hair regrowth after using oral minoxidil, topical minoxidil, dutasteride, multivitamins, and ketoconazole shampoo, with noticeable improvement in the hairline after 11 months. They reported a burning sensation on the scalp and questioned if single hair follicles could become multi-hair follicles.

The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

The conversation is about obtaining a finasteride prescription through Lemon Aid Health. The user is exploring the process and alternatives for getting the prescription sent to a pharmacy.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.

Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.